=== PAGE 1 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout, spacing, and structure:

DEPARTMENT OF HEALTH & HUMAN SERVICES
                                                      Public Health Service

                                                      Food and Drug Administration
                                                      Silver Spring, MD 20993

TRANSMITTED BY FACSIMILE

Fabio Almeida, MD
Phoenix Molecular Imaging Center
4540 East Cotton Gin Loop Ste 150
Phoenix, AZ 85040

RE:  [Redacted text] (b) (4)
           Sodium Acetate C-11
           MA 1

Dear Dr. Almeida:

The Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration
(FDA) has reviewed a webpage¹ entitled “Overview of PET/CT Imaging in Recurrent Prostate
Cancer-Current and Emerging Techniques” (webpage) that discusses the investigational new
drug Sodium Acetate C-11 (11C-Acetate), which is the subject of the above-referenced IND.
You are receiving this letter as the sponsor and principal investigator for that IND. The
webpage suggests in a promotional context that 11C-Acetate, an investigational new drug, is
safe and effective for the purpose for which it is being investigated or otherwise promotes the
drug. As a result, 11C-Acetate is misbranded under section 502(f)(1) of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) and in violation of section 301(k) of the FD&C Act. The
claims and presentations made on the webpage are concerning from a public health
perspective because they make conclusory representations in a promotional context
regarding the safety and efficacy of an investigational new drug that has not been approved
by the FDA and whose safety and efficacy have not yet been established.

Background

11C-Acetate is an investigational new drug for which there is no marketing authorization in
the United States. [Redacted text] (b) (4)

Misbranding of an Investigational Drug

Under section 502(f)(1) of the FD&C Act, a drug shall be deemed to be misbranded unless its
labeling bears adequate directions for use. Under FDA regulations, adequate directions for
use means directions under which the layman can use a drug safely and for the purposes for

¹ Found at http://www.drfabio.com/imagingblog/2018/1/9/overview-of-petct-imaging-in-recurrent-prostate-cancer-
current-and-emerging-techniques. Last accessed February 15, 2019.

Reference ID: 4391928

---
**Visual Elements Description:**

*   **Logo:** In the top-left corner of the page, there is a logo of the "DEPARTMENT OF HEALTH & HUMAN SERVICES". It features a stylized silhouette of a human figure with an outstretched arm, enclosed within a partial circle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES" is curved around the bottom portion of this circular design. The same text "DEPARTMENT OF HEALTH & HUMAN SERVICES" is also printed horizontally to the right of the logo.
